NIH Translational Science Center Becomes A (Cash-limited) Reality
NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.
You may also be interested in...
The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.
AesRx and its potential treatment for sickle cell disease are acquired by Baxter International, a measure of validation for the NCATS model of de-risking product development for rare and neglected diseases.
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Science Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translation Science Awards program.